This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
Demand for classic home-styled foods has increased during the pandemic as these well-known and beloved tastes often trigger pleasant, comforting memories for consumers.
Historically, bakery product developers’ main goal when selecting appropriate leaveners for a specific application was simply to attain a specific desired outcome every single time. Consistency mattered.
Willow Biosciences Inc. has advanced its work on its proprietary yeast strain for production of tetrahydrocannabinol (THC) and plans to commercially launch in the Canadian market.
The PhoeniX technology developed by Meiogenix controls the process of natural meiotic recombination and generates efficiently non–GM recombined yeast cells particularly for industrial strains where meiosis is impeded.
According to the report, the yeast market has been experiencing a positive growth for decades due to its increased application in food, feed, and other industrial sectors.
Functional Technologies Corp. said the FDA accepted research data for its proprietary acrylamide-preventing yeast to be generally regarded as safe (GRAS).